Ipsen inspired by portfolio effect

Based on its experience with human growth products, Ipsen Group believes a portfolio approach to specialist markets is better than bringing a single product to market. This was the rationale behind granting Inspiration Biopharmaceuticals Inc. a license to OBI-1, which gives the biotech a total of four hemophilia candidates, two of which are in late-stage development. The deal mitigates Ipsen's development risk while allowing it to acquire Inspiration once the products reach the market.

Inspiration received exclusive worldwide rights to OBI-1, a recombinant porcine Factor VIII that is expected to start Phase III testing this year to treat patients with acquired hemophilia or hemophilia A who have developed an inhibitory immune reaction to human Factor VIII...